- Home
- ATCH vs BTAI Comparison
ATCH vs BTAI Comparison
Compare ATCH & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATCH
- BTAI
- Stock Information
- Founded
- ATCH 2022
- BTAI 2017
- Country
- ATCH United States
- BTAI United States
- Employees
- ATCH N/A
- BTAI N/A
- Industry
- ATCH
- BTAI Biotechnology: Pharmaceutical Preparations
- Sector
- ATCH
- BTAI Health Care
- Exchange
- ATCH Nasdaq
- BTAI Nasdaq
- Market Cap
- ATCH 46.1M
- BTAI 48.3M
- IPO Year
- ATCH N/A
- BTAI 2018
- Fundamental
- Price
- ATCH $0.38
- BTAI $2.05
- Analyst Decision
- ATCH
- BTAI Buy
- Analyst Count
- ATCH 0
- BTAI 5
- Target Price
- ATCH N/A
- BTAI $32.80
- AVG Volume (30 Days)
- ATCH 46.4M
- BTAI 987.3K
- Earning Date
- ATCH 11-17-2025
- BTAI 11-12-2025
- Dividend Yield
- ATCH N/A
- BTAI N/A
- EPS Growth
- ATCH N/A
- BTAI N/A
- EPS
- ATCH 0.96
- BTAI N/A
- Revenue
- ATCH $10,856,612.00
- BTAI $868,000.00
- Revenue This Year
- ATCH N/A
- BTAI N/A
- Revenue Next Year
- ATCH N/A
- BTAI $614.78
- P/E Ratio
- ATCH $0.40
- BTAI N/A
- Revenue Growth
- ATCH 171.31
- BTAI N/A
- 52 Week Low
- ATCH $0.14
- BTAI $1.17
- 52 Week High
- ATCH $26.94
- BTAI $12.16
- Technical
- Relative Strength Index (RSI)
- ATCH 46.68
- BTAI 34.65
- Support Level
- ATCH $0.39
- BTAI $2.14
- Resistance Level
- ATCH $0.54
- BTAI $2.46
- Average True Range (ATR)
- ATCH 0.04
- BTAI 0.16
- MACD
- ATCH 0.00
- BTAI -0.00
- Stochastic Oscillator
- ATCH 20.17
- BTAI 9.03
About ATCH AtlasClear Holdings Inc. Common Stock
AtlasClear Holdings Inc is a fintech company. Its goal is to build a cutting-edge technology-enabled financial services firm that would create a more efficient platform for trading, clearing, settlement, and banking of evolving and financial products with a focus on financial services firms. It is a fintech-driven business-to-business platform that expects to power innovation in fintech, investing, and trading. The company believes it is positioned to provide a modern, mission-critical suite of solutions to its clients, enabling them to reduce their transaction costs and compete more effectively in their businesses.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.